ClinicalTrials.govclosed
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
ClinicalTrials.gov study NCT04509791. IPD Sharing: NO. Countries: 8. Publications: 2.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8